Tyrosine kinase inhibitor toxicity in the treatment of non-small-cell lung cancer: A bibliometric analysis (2009-2025)

Balymbetova L. Iztleuov Y.M. Ismagulova E.K. Kozhantayeva S. Balapasheva A.
27 February 2026

Medicine
2026 #105 Issue 9 e47860 pp.

BACKGROUND: Lung cancer incidence is increasing worldwide. Despite being cornerstone treatment modalities, both chemotherapy and targeted therapy are accompanied by treatment-related toxicities. The aim of this study is to identify key authors, leading countries, core journals, and keywords in research on treatment-related toxicities of tyrosine kinase inhibitors (TKIs) used for non-small-cell lung cancer (NSCLC). METHODS: A literature search was conducted in the Web of Science Core Collection database on June 28, 2025. The search strategy used the terms non-small cell lung cancer, toxicity, and tyrosine kinase inhibitors, and their combination with Boolean operators (AND, OR, NOT). Bibliometric analyzes were conducted using the Bibliometrix R-package along with the Biblioshiny interface for visualization and data exploration. RESULTS: A total of 366 publications on TKIs in NSCLC were identified between 2009 and 2025. Annual scientific production increased from 2 to 56 publications, with an average annual growth rate of 20%. China led with 580 papers, followed by Japan (381) and the United States (358). Harvard University ranked first among institutions (n = 46), followed by its medical affiliates, Pfizer, and the University of California System. The most productive journal was Lung Cancer (n = 18), whereas the Journal of Clinical Oncology had the highest impact factor (IF = 41.9). The most cited publication was Peters et al, which received 1830 citations, while average citation per article is 23. Analysis of author keywords revealed 3 major thematic clusters, encompassing strategies to overcome resistance, approaches to manage TKI-related toxicities, and studies on specific molecular subtypes (anaplastic lymphoma kinase, epidermal growth factor receptor). The most prevalent keywords were non-small cell lung cancer (32%) and osimertinib (23%), reflecting the central focus on third-generation TKIs in current research. CONCLUSIONS: Optimizing NSCLC therapy with TKIs requires proactive toxicity monitoring and integration of predictive biomarkers and real-world evidence to enhance efficacy and patient safety. Copyright

bibliometric analysis , non-small cell lung cancer , toxicity , tyrosine kinase inhibitors (TKIs)

Text of the article Перейти на текст статьи

Department of Otorhinolaryngology, West Kazakhstan Marat Ospanov Medical University, Republic of Kazakhstan, Aktobe, Kazakhstan
Department of Radiology, Marat Ospanov West Kazakhstan Medical University, Republic of Kazakhstan, Aktobe, Kazakhstan
Department of Pharmacology, Сlinical Pharmacology, West Kazakhstan Marat Ospanov Medical University, Republic of Kazakhstan, Aktobe, Kazakhstan

Department of Otorhinolaryngology
Department of Radiology
Department of Pharmacology

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026